Research Matters Blog


Updates from MUSC's Offices of Research Administration

FY 2017 Kirschstein-NRSA Budgetary Levels

NIH Notice Number: NOT-OD-17-072 establishes the FY 2017 Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels.

From the Notice:

This revised Notice supersedes NOT-OD-16-062, and establishes stipend levels for fiscal year (FY) 2017 Kirschstein-NRSA awards for undergraduate and predoctoral trainees and fellows, as shown in the table below.  The Training Related Expenses and Institutional Allowances for predoctoral trainees and fellows and the Tuition and Fees for all educational levels remain unchanged.  

The budgetary categories described in this Notice apply only to Kirschstein-NRSA awards made with FY 2017 funds.  All FY 2017 awards previously issued using FY 2016 stipend levels (NOT-OD-16-062) will be revised to adjust stipends to the FY 2017 level.

Appointments to institutional training grants that have already been awarded in FY 2017 must be amended to reflect the FY 2017 stipend levels once the training grant award has been adjusted by the NIH.  Amended appointments must be submitted through xTrain in the eRA Commons.  Retroactive adjustments or supplementation of stipends or other budgetary categories with Kirschstein-NRSA funds for an award made prior to October 1, 2016 are not permitted.

Note: The FY 2017 stipend and other budgetary levels for postdoctoral trainees and fellows was issued on December 15, 2016: NOT-OD-17-003

Stipends for FY 2017
Effective with all Kirschstein-NRSA awards made on or after October 1, 2017, the following annual stipend levels apply to all individuals receiving support through institutional research training grants or individual fellowships, including the Maximizing Access to Research Career (MARC) and Building Infrastructure Leading to Diversity (BUILD) programs.

Undergraduates in the MARC and BUILD Programs:  For institutional training grants (T34, TL4), two stipend levels may be used for undergraduate candidates: Freshmen/Sophomores and Juniors/Seniors. 

Career Level

Stipend for FY 2017

Monthly Stipend







Predoctoral Trainees and Fellows:  For institutional training grants (T32, T35, T90, TL1) and individual fellowships (F30, F31, F99), one stipend level is used for all predoctoral candidates, regardless of the level of experience.

Career Level

Years of Experience

Stipend for FY 2017

Monthly Stipend





Tuition and Fees, Training Related Expenses, and Institutional Allowance for Kirschstein-NRSA Recipients
The NIH will provide funds for Tuition and Fees, Training Related Expenses, and Institutional Allowance as detailed below.

A. Tuition and Fees

Undergraduate and Predoctoral Trainees and Fellows:  For institutional training grants (T32, T34, T35, T90, TL1, TL4) and individual fellowships (F30, F31, F99), an amount per predoctoral trainee equal to 60% of the level requested by the applicant institution, up to $16,000 per year, will be provided.  If the trainee or fellow is enrolled in a program that supports formally combined, dual-degree training (e.g., MD/PhD, DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), the amount provided per trainee or fellow will be 60% of the level requested, up to $21,000 per year.

B. Training Related Expenses on Institutional Training Grants
For institutional training grants (T32, T35, T90, TL1), these expenses (including health insurance costs) for predoctoral trainees will be paid at the amounts shown below for all competing and non-competing awards made with FY 2017 funds.  

  • Predoctoral Trainees: $4,200

C. Institutional Allowance for Individual Fellows
This allowance for predoctoral fellows will be paid at the amounts shown below for all competing and non-competing awards made with FY 2017 funds.

Institutional Allowance for individual fellows (F30, F31, F99) sponsored by non-Federal Public, Private, and Non-Profit Institutions (Domestic & Foreign, including health insurance):

  • Predoctoral Fellows: $4,200

Institutional Allowance for individual fellows (F30, F31, F99) sponsored by Federal and For-Profit Institutions (including health insurance):  

  • Predoctoral Fellows: $3,100

Relevant Policies
Current stipend levels are to be used in the preparation of future competing and non-competing NRSA institutional training grant and individual fellowship applications.  They will be administratively applied to all applications currently in the review process.

NRSA support is limited to 5 years for predoctoral trainees (6 years for dual-degree training, e.g., MD/PhD, DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD).

It should be noted that the maximum amount that NIH will award to support the compensation package for a graduate student research assistant remains at the zero level postdoctoral stipend, as described in NOT-OD-02-017.

Frequently Asked Questions Related to NRSA Tuition, Fees, and Health Insurance Policies:

Important REMINDER: NIH, AHRQ & NIOSH Policy on Appendix Materials

This message serves as a reminder for everyone at MUSC to adhere to the policy on Appendix Materials in funding applications submitted to the National Institutes of Health (NIH), the Agency for Healthcare Research and Quality (AHRQ), or the National Institute for Occupational Safety and Health (NIOSH). 

These federal agencies will administratively withdraw applications that include any disallowed materials in the Appendices.  Such an oversight will prohibit the application from getting peer reviewed and scored.

This information has been added to the ORSP web page for quick reference ( 

NOTE: the NIH FAQ link ( has been included to help clarify what is or is not allowed to be included in the Appendix Materials.


Notice NOT-OD-16-129 alerted the scientific research community of the elimination of most appendix materials for applications submitted to NIH, AHRQ or NIOSH for due dates on or after January 25, 2017. 

The NIH, AHRQ, and NIOSH strive to ensure fairness in peer review for all grant applicants by specifying the types and amount of application material that are accepted for peer review.  At the same time, these agencies appreciate both the need for applications to provide sufficient information to allow for an informed, expert review process and the importance of limiting the burden on peer reviewers.

Elimination of most appendix materials is intended to rectify inequities in the peer review process that can arise from submission of inappropriate or excessive appendix materials by some applicants and consideration of appendix materials in peer review by some, but not all reviewers. 


Appendix materials in peer review

All information submitted with an application except the cover letter, assignment request form and appendix information are assembled into a single application image for funding consideration. The different sections within the application image are specified in the application instructions and correspond to the standard review criteria.


  • All information required for the peer review process must be contained within those designated sections of the application image, unless the Funding Opportunity Announcement (FOA) specifies otherwise. 
  • Information that expands upon or complements information provided in any section of the application -- even if it is not required for the review -- is not allowed in the appendix unless it is listed in the allowed appendix materials (below).  (NOT-OD-11-080)
  • Unless the FOA requires that certain information be included in the appendix, failure of reviewers to address appendix materials in their reviews is not an acceptable basis for an appeal of initial peer review (NOT-OD-11-064).

Allowable appendix materials

Beginning with applications submitted to the NIH, AHRQ, or NIOSH for due dates on or after January 25, 2017, the only allowable appendix materials are:

For applications proposing clinical trials (unless the FOA provides other instructions for these materials):

  • Clinical trial protocols
  • Investigator's brochure from Investigational New Drug (IND), as appropriate

For all applications:

  • Blank informed consent/assent forms
  • Blank surveys, questionnaires, data collection instruments
  • FOA-specified items. 
    • If appendix materials are required in the FOA, review criteria for that FOA will address those materials, and applications submitted without those appendix materials will be considered incomplete and will not be reviewed.

Consequences for submitting disallowed appendix materials

Applications submitted for due dates on or after January 25, 2017 will be withdrawn and not reviewed if they are submitted with appendix materials that are not specifically listed in this Notice or the FOA as allowed or required.

FAQs on the NIH/AHRQ/NIOSH Appendix Policy

Related Announcements


Save the Date - PCORI Workshop
Save the Date - PCORI Workshop

The Office of Research Development is hosting a PCORI Workshop on July 18, 2018. The details are underdevelopment but I wanted to have faculty Save-the-Date.  The workshop will be 3-hours and two program officers from PCORI will be on campus to provide details regarding the organization, funding opportunities available, and an overview of the engagement requirements.  Dr. Kathleen Brady asked that PCORI also discuss plans for their sustainability. 

NIH Notice NOT-OD-17-062

Notice NOT-OD-17-062 announced a transition from the current NIH grant application forms (“FORMS-D”) to the next iteration of forms (“FORMS-E”) for due dates on or after January 25, 2018.

Highlights of the new FORMS-E will include:

  • Consolidation of human subjects, inclusion enrollment, and clinical trial information previously collected across multiple agency forms
  • Expansion and use of discrete form fields for clinical trial information to
    • provide the level of information needed for peer review;
    • lead applicants through clinical trial information collection requirements;
    • present key information to reviewers and agency staff in a consistent format; and
    • align with (where possible) and position us for future data exchange with
  • Incorporation of recent changes to R&R Budget and SBIR/STTR Information forms

Application guides for FORMS-E application packages will be posted to the How to Apply - Application Guide page no later than October 25, 2017.

  • New FOAs posted before October 25, 2017 with initial due dates on or after January 25, 2018 will be posted without application forms. Application packages will be added to these FOAs by November 10, 2017.

All NIH "parent" announcements that use standard due dates will be expired and reissued with new FOA numbers, FORMS-E application packages and instructions. The FORMS-E parent announcements will be posted no later than 60 days before their standard due date. For a transition period, both FORMS-D and FORMS-E parent announcements will be active. Applicants must choose the announcement with the appropriate application package for their due date (see table below).

All active FOAs with due dates both before and after January 25, 2018 will be updated to add FORMS-E application packages between October 25, 2017 and November 25, 2017. For a transition period, both FORMS-D and FORMS-E application packages will be active. Applicants must choose the appropriate application package for their due date when presented with both FORMS-D and FORMS-E application packages on the same FOA (see table below).

If your due date is…

You must use…

On or before January 24, 2018, including:

  • Applications submitted for due dates on or before January 24, 2018
  • Applications submitted under NIH Late Policy 2-week window of consideration for intended due dates on or before January 24, 2018
  • Applications submitted by February 7, 2018 under NIH Continuous Submission Policy for January 7, 2018 AIDS intended due date

FORMS-D application package

On or after January 25, 2018, including:

  • Applications submitted for due dates on or after January 25, 2018
  • All application types (New, Resubmission, Renewal, Revision)
  • Applications submitted early for intended dues dates on or after January 25, 2018

FORMS-E application package

Additional guide notices for individual FOAs with unique due date considerations will be issued as needed and referenced in the Related Notices section of each FOA.

Form Update Timing for Administrative Supplement, Successor-in-Interest (Type 6) and Change of Institution (Type 7) Parent Announcements

Parent announcements for administrative supplements and post award administrative actions (successor-in-interest and change of institution applications) do not have set due dates and, consequently, will follow a different timeline than other parent announcements.

The FOAs in the table below will be reissued with new FOA numbers, FORMS-E application packages and instructions on January 25, 2018. Applications started on or after January 25, 2018 must use the new FOAs and FORMS-E application packages.

These FOAs will expire on February 25, 2018 giving applicants one month to complete their initiated FORMS-D applications.


FOA Title


 Change of Grantee Organization (Type 7 Parent)


 Successor-in-Interest (Type 6 Parent)


 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Admin Supp)


 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)


 Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp)


Applications Proposing Clinical Trials

As previously announced, all applications involving clinical trials must be submitted to FOAs specifically designed for clinical trials beginning with due dates on or after January 25, 2018 (NOT-OD-16-147, NOT-OD-17-043).

NIH will take the following steps to accommodate this new policy:

  • Issue new clinical trial FOAs with clinical trial-specific review criteria, FORMS-E application packages, and FORMS-E instructions for due dates on or after January 25, 2018
  • Add a new "Clinical Trials" item to the table in Section II of all FOAs (just below "Application Types Allowed") which will include one of the following statements:
    • Only accepting applications that propose clinical trial(s)
    • Only accepting applications that do not propose clinical trials
    • Accepting applications that either propose or do not propose clinical trial(s)
  • Expire existing (FORMS-D) clinical trial FOAs by January 24, 2018


Shared Instrumentation Grant (S10) Program
Shared Instrumentation Grant (S10) Program

NIH Shared Instrumentation Grant (S10) Applications

Additional Information link:

New Funding Opportunities Resource: Grant Forward

How to Find Research Funding Opportunities at MUSC?

Grant Forward Database is a comprehensive database is available for MUSC faculty, postdocs, staff and students.

You can access Grant Forward at To use the full search features, including saved searches and personalized grant recommendations, you may create an account using your email address. We also encourage you to create your "Researcher Profile" to start receiving grant recommendations in your inbox. Select how often you would like to receive these messages - daily, weekly, monthly.

For tips on getting started in Grant Forward and training information on using the database, go to

For questions about the MUSC Funding Portal or assistance with navigating the many online resources to identify funding opportunities, please contact

NIH/AHRQ Font Requirements

NIH Notice NOT-OD-17-030 updates the NIH/AHRQ font guidance for applications due on or after January 25, 2017.

The Notice updates NIH’s recommended font list.  Please note that NIH no longer requires that black text be used within grant application attachments.

For applications submitted for due dates on or after January 25, 2017, text in PDF attachments must follow these minimum requirements:

  • Text Color: No restriction. Though not required, black or other high-contrast text colors are recommended since they print well and are legible to the largest audience.
  • Font size:  Must be 11 points or larger. Smaller text in figures, graphs, diagrams and charts is acceptable, as long as it is legible when the page is viewed at 100%.
  • Type density:  Must be no more than 15 characters per linear inch (including characters and spaces).
  • Line spacing: Must be no more than six lines per vertical inch.

Since some PDF converters may reduce font size, it is important to confirm that the final PDF document complies with the font requirements.

The following fonts are recommended, although other fonts (both serif and non-serif) are acceptable if they meet the above requirements.

  • Arial
  • Georgia
  • Helvetica
  • Palatino Linotype

Legibility is of paramount importance. Applications that include PDF attachments that do not conform to the minimum requirements listed above may be withdrawn from consideration.

Related Resources

Final Research Performance Progress Reports (Final RPPR)

NIH Notice NOT-OD-17-022 announced NIH’s implementation of Final Research Performance Progress Reports (Final RPPR or F-RPPR) effective January 1, 2017.

The Final RPPR will replace the Final Progress Report (FPR) and will be submitted via a new eRA Commons module.

A significant change with implementation of the F-RPPR is that in order to maximize public transparency, NIH will not maintain the current Type 2 policy which in accordance with NIHGPS Chapter 8.6.2 states that "whether funded or not" the progress report contained in the Type 2 application may serve in lieu of a separate final progress report.

NIH will request that organizations submit an "Interim-RPPR" while their renewal application (Type 2) is under consideration. In the event that the Type 2 is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment. If the Type 2 is not funded, the Interim-RPPR will be treated by NIH staff as the institution's Final-RPPR.

NIH is aligning its reporting requirement with other Federal research agencies and therefore will not be making any changes to the deadline for submitting the final report- i.e., the Final RPPR or Interim-RPPR must be submitted via eRA Commons no later than 120 calendar days from the period of performance end date. If a recipient fails to comply with this reporting requirement, NIH may take one or more enforcement actions, such as a decision not to make a non-competing continuation award, consistent with NIHGPS Chapter 8.5.2. NIH also plans to maintain the business rule in the RPPR module enabling institutional signing officials (SOs), at their discretion, to delegate submission of the Final RPPR or Interim-RPPR to the Program Director/Principal Investigator (PD/PI).

Note: Implementation of the Final RPPR for Small Business Innovation and Research (SBIR) and Small Business Technology Transfer (STTR) grants will occur approximately 2 months after implementation for all other NIH grants due to unique final reporting requirements under the Small Business Administration's SBIR/STTR Policy Directive.

FAQs and additional information pertaining to NIH's implementation of the F-RPPR will be available on the NIH RPPR website.

SCTR & FRD Technology Development Grants


SCTR & FRD Technology Development Grants


Key Dates:
Pre-Application Opens: January 2, 2017
Pre-Application Due: January 17, 2017
Invitation to Submit Full Application: January 31, 2017
Full Application Due: February 23, 2017

SCTR’s Therapeutics Translation Core (TTC), in conjunction with the MUSC Foundation for Research Development (FRD) and the MUSC Drug Discovery Core, aims to accelerate academic innovations into marketed products by providing gap funding of up to $25,000 to advance innovative, clinically relevant technologies. The awards support short-term (six month) studies designed to improve the commercial value of the technologies by strengthening the intellectual property (IP) and moving technologies further down the development pathway, thus increasing the partnerships and licensing opportunities with pharmaceutical and biotechnology companies.

The primary objective of the gap funding awards is to support projects that have a high chance of being commercialized, but that are not likely to get there without gap funding. Funds are intended to advance projects to the next developmental milestone by enabling investigators to conduct additional experiments, such as those that

  • Optimize compounds, conduct toxicology studies, or help define a pharmacological target or translational biomarker
  • Prototype a device
  • Build or validate a software program

Please note:

This RFA is open to advance technologies protected by, or protectable by, IP that is assigned or assignable to MUSC pursuant the MUSC IP Policy. If a patent or patent application is not currently assigned to FRD, a Record of Invention must be on file with FRD at least one month in advance of the Pre-Application open date.

For more information, contact Ford Simmons at